VIR-2218+VIR-3434 is an antisense rnai oligonucleotide commercialized by Vir Biotechnology, with a leading Phase II program in Hepatitis B. According to Globaldata, it is involved in 12 clinical trials, of which 2 were completed, 7 are ongoing, and 3 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of VIR-2218+VIR-3434’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for VIR-2218+VIR-3434 is expected to reach an annual total of $131 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

VIR-2218+VIR-3434 Overview

VIR-2218 is under development for the treatment of hepatitis B and D virus infections. It is administered through subcutaneous route and acts by targeting hepatitis B virus (HBV) genome including HBsAg. It is a RNAi therapeutic developed based on enhanced stabilization chemistry (ESC)-GalNAc-conjugate delivery platform technology.

Vir Biotechnology Overview

Vir Biotechnology (Vir) is a biotechnology company which carries out the development of therapeutic products to prevent and treat serious infectious diseases. It develops treatments for viral and bacterial diseases and those that induce protective and therapeutic immune responses. The company undertakes a multi-program, multi-platform approach to apply these breakthroughs. Vir primarily focuses on chronic infectious diseases including hepatitis B, tuberculosis, and HIV; respiratory diseases, including influenza, respiratory syncytial virus (RSV), and metapneumovirus (MPV); and healthcare-acquired infections. It operates in Portland, Oregon, Boston, Massachusetts, Bellinzona, Switzerland. Vir is headquartered in San Francisco, California, the US.

The company reported revenues of (US Dollars) US$1,095.4 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$76.4 million in FY2020. The operating profit of the company was US$420.8 million in FY2021, compared to an operating loss of US$297 million in FY2020. The net profit of the company was US$528.6 million in FY2021, compared to a net loss of US$298.7 million in FY2020.

For a complete picture of VIR-2218+VIR-3434’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.